Ventri Point is a company is dedicated to improving the diagnosis of heart disease using patented technology combined with traditional ultrasound and MRI imaging. Pediatric and adult patients will benefit from the companys VentriPoint Diagnostic System, which extends the monitoring necessary to accurately evaluate the right and left ventricles of the heart. The VentriPoint Diagnostic System utilizes images obtained from devices already in use making it economical very cost effective for hospitals and clinics alike. It provides 3-d models and critical measurements for a fraction of the cost and time of MRI or three-dimensional ultrasound methods. Future applications to the VentriPoint Diagnostic System are projected to be diagnostic analysis of Pulmonary Hypertension, Heart Failure, and Coronary Artery Disease. VentriPoint traded as VPT on the TSX in Canada and VPTDF.PK on the OTC as of March 2012 trades around .9 cents a share --- with a market cap of 19.5 million dollars. Today we have with us Dr George Adams, CEO of VentriPoint: For more information about VentriPoint Diagnostics Ltd., go to ventripoint.com. For Crwenewswire thanks for joining us and have a great day. This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of the effectiveness of management's strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements and changing price and market conditions. No assurance can be given that these are all the factors that could cause actual results to vary materially from the forward-looking statements. Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.ae report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

CategoryNews and Politics

Tags VentriPoint, TSXVVPT, VPT, PinksheetsVPTDF, CVEVPT, Congenital heart disease

Uploaded 2012-03-12 00:35:03